Walgreens October Sales Increase 6.1 Percent
November 05 2013 - 7:00AM
Business Wire
Walgreens (NYSE: WAG) (Nasdaq: WAG) had October sales of $6.37
billion, an increase of 6.1 percent from $6.0 billion for the same
month in fiscal 2013.
Total front-end sales increased 3.5 percent compared with the
same month in fiscal 2013, while comparable store front-end sales
increased 2.3 percent. Customer traffic in comparable stores
increased 0.6 percent while basket size increased 1.7 percent.
Prescriptions filled at comparable stores increased by 5.7
percent in October and increased 6.2 percent on a calendar
day-shift adjusted basis. This year’s October had one additional
Thursday and one fewer Monday compared with October 2012. These
calendar shifts negatively impacted prescriptions filled at
comparable stores by 0.5 percentage point.
Prescriptions filled at comparable stores also were positively
impacted by 1.1 percentage points due to more flu shots versus last
year and were negatively impacted by 0.2 percentage point due to
lower incidence of flu in this year’s October.
October pharmacy sales increased by 7.8 percent, while
comparable store pharmacy sales increased 7.9 percent and increased
by a calendar day-shift adjusted 8.4 percent. Calendar day shifts
negatively impacted pharmacy sales in comparable stores by 0.5
percentage point. Calendar day-shift adjusted comparable store
pharmacy sales were negatively impacted by 1.0 percentage point due
to generic drug introductions in the last 12 months, and were
positively impacted by 0.7 percentage point due to more flu shots
versus last year. Pharmacy sales accounted for 65.5 percent of
total sales for the month.
Flu shots administered at pharmacies and clinics season to date
were more than 4.9 million versus nearly 3.6 million last year.
Sales in comparable stores increased by 5.8 percent in October.
Calendar day shifts negatively impacted total comparable sales by
0.3 percentage point, while generic drug introductions in the last
12 months negatively impacted total comparable sales by 0.7
percentage point.
Calendar 2013 sales to date were $60.47 billion, an increase of
4.3 percent from $57.97 billion in 2012.
Fiscal 2014 year-to-date sales for the first two months were
$12.29 billion, up 7.0 percent from $11.49 billion in the
comparable period in fiscal 2013.
Walgreens opened 14 stores during October, including four
relocations, and closed two.
October Comparable Sales and Prescriptions
Filled
Actual
Calendar Shift
Impact
Generics
Impact
Cough, Cold, Flu
Impact
Flu Shot
Impact
Total Comp Sales 5.8% - 0.3% - 0.7% - 0.1% 0.5% Comp Front
End 2.3% - - - - Comp Rx Sales 7.9% - 0.5% - 1.0% - 0.1% 0.7% Comp
Rx Scripts 5.7%* - 0.5% - - 0.2% 1.1%
* Includes +1.9 percentage points from patients filling more
90-day prescriptions
On Oct. 31, Walgreens operated 8,597 locations in all 50 states,
the District of Columbia, Puerto Rico, Guam and the U.S. Virgin
Islands. That includes 8,131 drugstores, 101 more than a year ago,
including five net stores acquired over the last 12 months. The
company also operates infusion and respiratory services facilities,
specialty pharmacies and mail service facilities. Its Take Care
Health Systems subsidiary manages more than 750 in-store convenient
care clinics and worksite health and wellness centers.
Please note: Sales numbers and the adjustments shown in the
table are preliminary, unaudited and subject to revision.
Comparable stores are defined as those drugstore locations open for
at least 12 consecutive months without closure for seven or more
consecutive days and without a major remodel or a natural disaster
in the past 12 months. Acquired operating locations and relocations
are not included as comparable stores for the first 12 months after
the acquisition or relocation.
Cautionary Note Regarding Forward-Looking Statements: Statements
in this release that are not historical are forward-looking
statements made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. Words such as
"expect," “likely,” "outlook," “forecast,” "would," "could,"
"should," “can,” “will,” "project," "intend," "plan," "goal,”
“target,” “continue," "sustain," “synergy,” "on track," "believe,"
"seek," "estimate," "anticipate," "may," “possible,” "assume," and
variations of such words and similar expressions are intended to
identify such forward-looking statements. These forward-looking
statements are not guarantees of future performance and involve
risks, assumptions and uncertainties, including, but not limited
to, those described in Item 1A (Risk Factors) of our most recent
Annual Report on Form 10-K which is incorporated herein by
reference, and in other documents that we file or furnish with the
Securities and Exchange Commission. Should one or more of these
risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results may vary materially
from those indicated or anticipated by such forward-looking
statements. Accordingly, you are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date they are made. Except to the extent required by law,
Walgreens does not undertake, and expressly disclaims, any duty or
obligation to update publicly any forward-looking statement after
the date of this release, whether as a result of new information,
future events, changes in assumptions or otherwise.
WalgreensMedia contact:Jim Graham, 847-315-2925Investor
contacts:Rick Hans, CFA, 847-315-2385Ashish Kohli, CFA,
847-315-3810http://news.walgreens.com@WalgreensNewsfacebook.com/Walgreens
West Africa Gold (NASDAQ:WAGI)
Historical Stock Chart
From Jun 2024 to Jul 2024
West Africa Gold (NASDAQ:WAGI)
Historical Stock Chart
From Jul 2023 to Jul 2024